Liberum Capital Keeps a Buy Rating on Oxford BioMedica (OXBDF)
Liberum Capital analyst Liberum Capital reiterated a Buy rating on Oxford BioMedica (OXBDF) on June 8. The company’s shares closed last Monday at $10.30.
Oxford BioMedica has an analyst consensus of Strong Buy, with a price target consensus of $19.00, an 80.4% upside from current levels. In a report issued on May 28, H.C. Wainwright also reiterated a Buy rating on the stock with a £14.50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.75 and a one-year low of $4.51. Currently, Oxford BioMedica has an average volume of 5,688.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OXBDF in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. It operates through the Platform and Product segment. The Platform segment consists of the revenue generating bioprocessing and process development activities undertaken for third parties. The Product segment includes clinical and preclinical development of in vivo and ex vivo gene and cell therapy products which are owned by the group. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1996 and is headquartered in Oxford, the United Kingdom.
Read More on OXBDF: